Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

UBS
Julphar
Cipla
Queensland Health
Healthtrust
Chubb
Moodys
Cerilliant
Argus Health

Generated: November 13, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 021959

« Back to Dashboard

NDA 021959 describes ORAPRED ODT, which is a drug marketed by Concordia Pharms Inc and is included in one NDA. It is available from two suppliers. There is one patent protecting this drug. Additional details are available on the ORAPRED ODT profile page.

The generic ingredient in ORAPRED ODT is prednisolone sodium phosphate. There are eighty-eight drug master file entries for this compound. Twenty-three suppliers are listed for this compound. Additional details are available on the prednisolone sodium phosphate profile page.
Summary for 021959
Tradename:ORAPRED ODT
Applicant:Concordia Pharms Inc
Ingredient:prednisolone sodium phosphate
Patents:1
Formulation / Manufacturing:see details
Pharmacology for NDA: 021959
Suppliers and Packaging for NDA: 021959
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
ORAPRED ODT prednisolone sodium phosphate TABLET, ORALLY DISINTEGRATING;ORAL 021959 NDA Concordia Pharmaceuticals Inc. 59212-700 59212-700-48 8 BLISTER PACK in 1 CARTON (59212-700-48) > 6 TABLET, ORALLY DISINTEGRATING in 1 BLISTER PACK
ORAPRED ODT prednisolone sodium phosphate TABLET, ORALLY DISINTEGRATING;ORAL 021959 NDA Concordia Pharmaceuticals Inc. 59212-701 59212-701-02 1 BLISTER PACK in 1 CARTON (59212-701-02) > 2 TABLET, ORALLY DISINTEGRATING in 1 BLISTER PACK

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET, ORALLY DISINTEGRATING;ORALStrengthEQ 10MG BASE
Approval Date:Jun 1, 2006TE:ABRLD:Yes
Patent:➤ Try a Free TrialPatent Expiration:Nov 24, 2019Product Flag?YSubstance Flag?Delist Request?

Profile for product number 002

Active Rx/OTC/Discontinued:RXDosage:TABLET, ORALLY DISINTEGRATING;ORALStrengthEQ 15MG BASE
Approval Date:Jun 1, 2006TE:ABRLD:Yes
Patent:➤ Try a Free TrialPatent Expiration:Nov 24, 2019Product Flag?YSubstance Flag?Delist Request?

Profile for product number 003

Active Rx/OTC/Discontinued:RXDosage:TABLET, ORALLY DISINTEGRATING;ORALStrengthEQ 30MG BASE
Approval Date:Jun 1, 2006TE:ABRLD:Yes
Patent:➤ Try a Free TrialPatent Expiration:Nov 24, 2019Product Flag?YSubstance Flag?Delist Request?

Expired US Patents for NDA 021959

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Concordia Pharms Inc ORAPRED ODT prednisolone sodium phosphate TABLET, ORALLY DISINTEGRATING;ORAL 021959-003 Jun 1, 2006 ➤ Try a Free Trial ➤ Try a Free Trial
Concordia Pharms Inc ORAPRED ODT prednisolone sodium phosphate TABLET, ORALLY DISINTEGRATING;ORAL 021959-001 Jun 1, 2006 ➤ Try a Free Trial ➤ Try a Free Trial
Concordia Pharms Inc ORAPRED ODT prednisolone sodium phosphate TABLET, ORALLY DISINTEGRATING;ORAL 021959-002 Jun 1, 2006 ➤ Try a Free Trial ➤ Try a Free Trial
Concordia Pharms Inc ORAPRED ODT prednisolone sodium phosphate TABLET, ORALLY DISINTEGRATING;ORAL 021959-002 Jun 1, 2006 ➤ Try a Free Trial ➤ Try a Free Trial
Concordia Pharms Inc ORAPRED ODT prednisolone sodium phosphate TABLET, ORALLY DISINTEGRATING;ORAL 021959-001 Jun 1, 2006 ➤ Try a Free Trial ➤ Try a Free Trial
Concordia Pharms Inc ORAPRED ODT prednisolone sodium phosphate TABLET, ORALLY DISINTEGRATING;ORAL 021959-003 Jun 1, 2006 ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Deloitte
Chinese Patent Office
Accenture
Fuji
McKesson
Medtronic
Julphar
Healthtrust
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.